326 related articles for article (PubMed ID: 32456317)
1. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.
Rajaram P; Rivera A; Muthima K; Olveda N; Muchalski H; Chen QH
Molecules; 2020 May; 25(10):. PubMed ID: 32456317
[TBL] [Abstract][Full Text] [Related]
2. Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants.
Shiota M; Dejima T; Yamamoto Y; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Kajioka S; Uchiumi T; Eto M
Cancer Sci; 2018 Oct; 109(10):3224-3234. PubMed ID: 30051622
[TBL] [Abstract][Full Text] [Related]
3. ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer.
Fizazi K; Albiges L; Loriot Y; Massard C
Expert Rev Anticancer Ther; 2015; 15(9):1007-17. PubMed ID: 26313416
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).
Penning TM
J Steroid Biochem Mol Biol; 2015 Sep; 153():105-13. PubMed ID: 26032458
[TBL] [Abstract][Full Text] [Related]
5. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.
Lallous N; Volik SV; Awrey S; Leblanc E; Tse R; Murillo J; Singh K; Azad AA; Wyatt AW; LeBihan S; Chi KN; Gleave ME; Rennie PS; Collins CC; Cherkasov A
Genome Biol; 2016 Jan; 17():10. PubMed ID: 26813233
[TBL] [Abstract][Full Text] [Related]
6. Developing a Novel Enzalutamide-Resistant Prostate Cancer Model via AR F877L Mutation in LNCaP Cells.
Wang R; Ma S; Xu N; Gan Y; Li P; Zhang J; Zhang Z; Gu Q; Xiang J
Curr Protoc; 2024 Apr; 4(4):e1033. PubMed ID: 38652202
[TBL] [Abstract][Full Text] [Related]
7. TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.
Semaan L; Mander N; Cher ML; Chinni SR
BMC Cancer; 2019 Oct; 19(1):972. PubMed ID: 31638934
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment.
Kregel S; Wang C; Han X; Xiao L; Fernandez-Salas E; Bawa P; McCollum BL; Wilder-Romans K; Apel IJ; Cao X; Speers C; Wang S; Chinnaiyan AM
Neoplasia; 2020 Feb; 22(2):111-119. PubMed ID: 31931431
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor antagonists in castration-resistant prostate cancer.
Rathkopf D; Scher HI
Cancer J; 2013; 19(1):43-9. PubMed ID: 23337756
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway.
Sekhar KR; Wang J; Freeman ML; Kirschner AN
PLoS One; 2019; 14(4):e0214670. PubMed ID: 30933998
[TBL] [Abstract][Full Text] [Related]
11. New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.
Centenera MM; Selth LA; Ebrahimie E; Butler LM; Tilley WD
Cold Spring Harb Perspect Med; 2018 Dec; 8(12):. PubMed ID: 29530945
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone.
Masoodi KZ; Eisermann K; Yang Z; Dar JA; Pascal LE; Nguyen M; O'Malley K; Parrinello E; Feturi FG; Kenefake AN; Nelson JB; Johnston PA; Wipf P; Wang Z
Endocrinology; 2017 Oct; 158(10):3152-3161. PubMed ID: 28977599
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Novel Anti-Resistance AR Antagonists Guided by Funnel Metadynamics Simulation.
Chen H; Zhou Y; Wang X; Chai X; Wang Z; Wang E; Xu L; Hou T; Li D; Duan M
Adv Sci (Weinh); 2024 May; 11(19):e2309261. PubMed ID: 38481034
[TBL] [Abstract][Full Text] [Related]
14. ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature.
Vellky JE; Kirkpatrick BJ; Gutgesell LC; Morales M; Brown RM; Wu Y; Maienschein-Cline M; Notardonato LD; Weinfeld MS; Nguyen RH; Brister E; Sverdlov M; Liu L; Xu Z; Kregel S; Nonn L; Vander Griend DJ; Reizine NM
Clin Cancer Res; 2024 Apr; 30(8):1530-1543. PubMed ID: 38306015
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance.
Li C; Lanman NA; Kong Y; He D; Mao F; Farah E; Zhang Y; Liu J; Wang C; Wei Q; Liu X
J Biol Chem; 2020 Apr; 295(16):5470-5483. PubMed ID: 32184358
[TBL] [Abstract][Full Text] [Related]
16. Role of BioResponse 3,3'-Diindolylmethane in the Treatment of Human Prostate Cancer: Clinical Experience.
Li Y; Sarkar FH
Med Princ Pract; 2016; 25 Suppl 2(Suppl 2):11-7. PubMed ID: 26501150
[TBL] [Abstract][Full Text] [Related]
17. Drug-drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors.
Appukkuttan S; Ko G; Fu C; Bannister B; Kong SX; Jhaveri J; Freedland SJ
Expert Rev Anticancer Ther; 2024 May; 24(5):325-333. PubMed ID: 38469875
[TBL] [Abstract][Full Text] [Related]
18. TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures.
Sha K; Yeh S; Chang C; Nastiuk KL; Krolewski JJ
Oncotarget; 2015 Sep; 6(28):25726-40. PubMed ID: 26327448
[TBL] [Abstract][Full Text] [Related]
19. Enzalutamide and leuprolide acetate in non-metastatic hormone-sensitive prostate cancer: the sooner the better?
Giunta EF; Gasperoni L; De Giorgi U
Future Oncol; 2024 Feb; 20(4):163-166. PubMed ID: 38323376
[No Abstract] [Full Text] [Related]
20. Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).
Gupta E; Guthrie T; Tan W
BMC Urol; 2014 Jul; 14():55. PubMed ID: 25062956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]